Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care ontario clinical practice guideline

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3436-3448

  Basch, Ethan ^a   Loblaw, D Andrew ^c   Oliver, Thomas K ⁱ   Carducci, Michael ^j,m   Chen, Ronald C ^a   Frame, James N ^k   Garrels, Kristina ^l   Hotte, Sebastien ^e   Kattan, Michael W ^m   Raghavan, Derek ^b   Saad, Fred ^h   Taplin, Mary Ellen ⁿ   Walker Dilks, Cindy ^e,f   Williams, James ^o   Winquist, Eric ^g   Bennett, Charles L ^p   Wootton, Ted ^d   Rumble, R Bryan ⁱ   Dusetzina, Stacie B ^a   Virgo, Katherine S ^q  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Carolina Healthcare System   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d Patient Representatives   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f Cancer Care Ontario   (New Zealand)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k CHARLESTON AREA MEDICAL CENTER   (United States)

^l Private Practice   (United States)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o Pennsylvania Prostate Cancer Coalition   (United States)

^p University of South Carolina   (United States)

^q EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HYDROCORTISONE; IPILIMUMAB; KETOCONAZOLE; MEGESTROL ACETATE; MITOXANTRONE; NILUTAMIDE; OPIATE; ORTERONEL; PREDNISONE; RA 223; RADIOPHARMACEUTICAL AGENT; SATRAPLATIN; SIPULEUCEL T; SUNITINIB; TASQUINIMOD; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; PHENYLTHIOHYDANTOIN; TAXOID;

ADD ON THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BRIEF PAIN INVENTORY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT OF CANCER THERAPY PROSTATE; GOOD CLINICAL PRACTICE; HEALTH CARE DISPARITY; HOT FLUSH; HUMAN; MEDICAL SOCIETY; METASTASIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TIME TO TREATMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; MALE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PSYCHOLOGY;

ANDROSTADIENES; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 84908450488     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8404     Document Type: Article

References (65)

1. American Cancer Society: Cancer Facts and Figures 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
2. Advisory Committee on Cancer Statistics: Canadian Cancer Statistics 2013. Toronto, Ontario, Canada, Canadian Cancer Society, 2013
3. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596-1605, 2007
4. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005
5. Winquist E, Waldron T, Berry S, et al: Nonhormonal systemic therapy in men with hormonerefractory prostate cancer and metastases: A systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 6:112, 2006
6. Basch EM, Somerfield MR, Beer TM, et al: American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 25:5313-5318, 2007
7. Galsky MD, Vogelzang NJ: Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21:2135-2144, 2010
8. Loblaw DA, Walker-Dilks C, Winquist E, et al: Systemic therapy in men with metastatic castrationresistant prostate cancer: A systematic review. Clin Oncol (R Coll Radiol) 25:406-430, 2013
9. Nelson JB, Fizazi K, Miller K, et al: Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118:5709-5718, 2012
10. James ND, Caty A, Payne H, et al: Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebocontrolled, randomized phase II trial. BJU Int 106: 966-973, 2010
11. Pili R, Häggman M, Stadler WM, et al: Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29:4022-4028, 2011
12. Armstrong AJ, Häggman M, Stadler WM, et al: Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res 19:6891-6901, 2013
13. Carducci MA, Saad F, Abrahamsson PA, et al: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966, 2007
14. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
15. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
16. Beer TM, Armstrong AJ, Sternberg CN, et al: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. J Clin Oncol 32, 2014 (suppl 4; abstr LBA1)
17. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al: 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: A randomised, phase 3 trial. Lancet Oncol 14:117-124, 2013
18. Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
19. Fossa SD, Jacobsen AB, Ginman C, et al: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study. Eur Urol 52: 1691-1699, 2007
20. Machiels JP, Mazzeo F, Clausse M, et al: Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26:5261-5268, 2008
21. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012
22. Quinn DI, Tangen CM, Hussain M, et al: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial. Lancet Oncol 14:893-900, 2013
23. Sonpavde G, Matveev VB, Burke JM, et al: A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 29:295s, 2011 (suppl; abstr 4528)
24. Sternberg CN, Dumez H, Van Poppel H, et al: Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): An EORTC multicenter, randomized phase II study in patients with castrationresistant prostate cancer. Ann Oncol 20:1264-1269, 2009
25. Mathew P, Thall PF, Bucana CD, et al: Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13:5816-5824, 2007
26. Higano C, Saad F, Somer B, et al: A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). J Clin Oncol 27, 2009 (suppl; abstr LBA150)
27. Small E, Demkow T, Gerritsen W, et al: A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castrationresistant prostate cancer (CRPC). J Clin Oncol 27, 2009 (suppl; abstr 7)
28. Scher HI, Jia X, Chi K, et al: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29:2191-2198, 2011
29. Beer T, Ryan C, Venner P, et al: Doubleblinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: A report from ASCENT investigators. J Clin Oncol 25:669-674, 2007
30. Fizazi KS, Higano CS, Nelson JB, et al: Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 31:1740-1747, 2013
31. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
32. de Bono J, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
33. Sternberg CN, Petrylak DP, Sartor O, et al: Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 27:5431-5438, 2009
34. Ou Y, Michaelson M, Sengeløv L, et al: Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU-P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 29:292s, 2011 (suppl; abstr 4515)
35. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
36. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
37. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
38. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med [epub ahead of print on June 1, 2014]
39. Mohler JL, Armstrong AJ, Bahnson RR, et al: Prostate cancer, version 3.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081-1087, 2012
40. Cookson MS, Roth BJ, Dahm P, et al: Castration-resistant prostate cancer: AUA guideline. J Urol 190:429-438, 2013
41. Bahl A, Oudard S, Tombal B, et al: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402-2408, 2013
42. Exelixis: Study of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2). www.clinicaltrials.gov/ct2/show/NCT01522443
43. Harland S, Staffurth J, Molina A, et al: Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49:3648-3657, 2013
44. Sternberg CN, Molina A, North S, et al: Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 24:1017-1025, 2013
45. Sweeney C, Chen YH, Carducci MA, et al: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormonesensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32, 2014 (suppl 15s; abstr LBA2)
46. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
47. Higano CS, Schellhammer PF, Small EJ, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670-3679, 2009
48. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004
49. Nakabayashi M, Xie W, Regan MM, et al: Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107:975-981, 2006
50. Manikandan R, Srirangam SJ, Pearson E, et al: Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: A prospective randomized trial. Urol Int 75:217-221, 2005
51. Fossa SD, Slee PH, Brausi M, et al: Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organisation for Research and Treatment of Cancer genitourinary group. J Clin Oncol 19:62-71, 2001
52. Dawson NA, Conaway M, Halabi S, et al: A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B study 9181. Cancer 88:825-834, 2000
53. Patel SR, Kvols LK, Hahn RG, et al: A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 66:655-658, 1990
54. Logothetis CJ, Basch E, Molina A, et al: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13:1210-1217, 2012
55. De Wit R, Fizazi K, Jinga V, et al: Phase 3, randomized, placebo-controlled trial of northern (TAK-700) plus prednisone in patients (pts) with chemotherapy-na?ve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). J Clin Oncol 32, 2014 (suppl 15s; abstr 5008)
56. Dreicer R, Jones R, Oudard S, et al: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). J Clin Oncol 32, 2014 (suppl 4; abstr 7)
57. Active Biotech AB: A study of tasquinimod in men with metastatic castrate resistant prostate cancer. www.clinicaltrials.gov/ct2/show/NCT01234311
58. Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
59. Truven Health Analytics: Life Sciences. http://www.truvenhealth.com/your-healthcare-focus/pharmaceutical-and-medical-device/data- databases-and-online-tools.aspx
60. Memorial Sloan Kettering Cancer Center: Cost of Cancer Drugs. http://www.mskcc.org/research/healthpolicy-outcomes/cost-drugs
61. Bach PB, Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
62. Weeks JC, Catalano PJ, Cronin A, et al: Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616-1625, 2012
63. National Institutes of Health: NIH-funded study shows increased survival in men with metastatic prostate cancer who receive chemotherapy when starting hormone therapy. http://www .nih.gov/news/health/dec2013/nci-05.htm
64. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101, 2012
65. Smith TJ, Temin S, Alesi ER, et al: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clin Oncol 30:880-887, 2012